VKTX - CIK 0001607678
Viking Therapeutics, Inc. (VKTX) reported revenue of $0.00 for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $0.00 | - |
| FY 2024 | $0.00 | - |
| FY 2023 | $0.00 | - |
| FY 2022 | $0.00 | - |
| FY 2021 | $0.00 | - |
| FY 2020 | $0.00 | - |
| FY 2019 | $0.00 | - |
| FY 2018 | $0.00 | - |
| FY 2017 | $0.00 |
Viking Therapeutics, Inc. (VKTX) reported revenue of $0.00 for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2014 and fiscal 2025, Viking Therapeutics, Inc.'s revenue grew from $0.00 to $0.00.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| FY 2016 | $0.00 | - |
| FY 2015 | $0.00 | - |
| FY 2014 | $0.00 | - |